Company / Cost of Revenue
ADMA Biologics, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$217.4M
FY2025
5-year range
$79.8M / $217.4M
FY2021-FY2025
Trend
+5.1%
vs FY2024
Sector context
#34 of 85
Health Care
What the data says
At $217M, ADMA Biologics, Inc.'s cost of revenue ranks #52 of 85 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $80M in FY2022 to $217M in FY2025.
Based on SEC 10-K filings.
$217M in FY2025 with a 5-year CAGR of +28.8%.
Increased from $169M to $217M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +39.7%
- 5-Year CAGR
- +28.8%
- 10-Year CAGR
- -
Sector benchmark
#52 of 85 in Health CareTop 60% of 85This company $217.4M Sector average $2.0B
▼
-89.0% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +28.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 5.1% year-over-year.
- Ranks #34 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $217.4M | +5.1% |
| FY2024 | $206.9M | +22.2% |
| FY2023 | $169.3M | +112.2% |
| FY2022 | $79.8M | -0.0% |
| FY2021 | $79.8M | +30.1% |
| FY2020 | $61.3M | +55.2% |
| FY2019 | $39.5M | -6.4% |
| FY2018 | $42.2M | +2526.4% |
| FY2017 | $1.6M | +0.0% |
| FY2016 | $1.6M | -57.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026